CAPR Stock Collapses As FDA, Lawyers Hammer Deramiocel Data

Capricor Therapeutics Inc. faces intensified pressure as critical clinical trial concerns emerge, and its stocks have been trading down by -55.4 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CAPR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For CAPR Traders

FDA briefing documents on Capricor Therapeutics’ deramiocel questioned effectiveness, stats methods, and risk–benefit, saying the evidence does not provide substantial proof of effectiveness.
After the harsh FDA staff critique, CAPR plunged roughly 60–70%, sliding toward the $7 area with intraday drops of about 62–65%.
Multiple law firms, including Kehoe, Block & Leviton, Rosen, Levi & Korsinsky, and Howard G. Smith, launched securities-fraud investigations tied to Capricor’s prior deramiocel statements.
FDA staff flagged post-randomization and post-hoc changes to deramiocel’s primary endpoint and statistical plan, raising questions about data handling and integrity.
A Cantor Fitzgerald analyst called the FDA package an “ugly picture,” underscoring elevated regulatory and litigation risk for Capricor Therapeutics and CAPR traders.

Quick Financial Overview

Capricor Therapeutics, trading under CAPR, just went from steady biotech story to full-on crash chart. In mid-July, CAPR was closing around $20, with a recent high above $23. By 2026/07/27, after the FDA briefing documents on deramiocel hit, the stock closed near $7 and has stayed pinned in the mid–$6 range. That is a destruction of roughly two-thirds of the market value in days.

On the fundamentals, the numbers tell traders this is still a classic clinical-stage biotech. Capricor Therapeutics posted quarterly revenue essentially at zero, with a pretax profit margin near -489% and a net loss of about $33.9M. Operating cash flow ran roughly -$29.3M, and free cash flow was about -$34.4M for the quarter. CAPR has a strong current ratio near 8.4 and low debt, but that cushion can shrink fast if cash burn stays high and deramiocel’s path is blocked.

More Breaking News

Valuation is tricky now. Price-to-book for Capricor Therapeutics screens rich around 7x, based on book value per share of about $4.82, even after the crash. For traders, that says CAPR is no longer trading on balance sheet support. It is trading on binary headline risk around deramiocel and the legal overhang.

Why Traders Are Watching CAPR After The FDA Shock

For active traders, CAPR just turned into a textbook high-volatility, headline-driven name. The trigger was the FDA’s advisory committee briefing documents on deramiocel, Capricor Therapeutics’ lead cell therapy for Duchenne-associated cardiomyopathy. Regulators didn’t just quibble over a secondary measure. They questioned whether the HOPE program showed substantial evidence of effectiveness at all.

The FDA staff leaned on earlier data cuts that, in their view, failed to support Capricor Therapeutics’ more optimistic narrative. They highlighted post-randomization and post-hoc changes to the primary endpoint and the statistical analysis plan. When a regulator uses phrases like “unfavorable benefit–risk” and draws attention to shifting endpoints, traders know the approval odds have shrunk dramatically.

The market reaction in CAPR was brutal and fast. Shares of Capricor Therapeutics dropped more than 60%, ripping from the high teens and low $20s down into single digits. Intraday, CAPR saw 62–65% declines as selling cascaded. This was pure momentum unwinding: funds that had bet on deramiocel approval rushed for the exits, and short sellers took control of the tape.

At the same time, legal pressure piled on. Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith all announced investigations or class-action preparations tied to CAPR. Their common theme: whether Capricor Therapeutics misled markets by painting deramiocel data and FDA feedback as “strong” or “supportive” when regulators later pushed back hard.

One law-firm release cited a Cantor Fitzgerald analyst who said the FDA documents painted an “ugly picture” and questioned data integrity. For traders, when the sell side, the FDA, and plaintiffs’ attorneys all line up on the same side of the trade, sentiment on CAPR does not just weaken — it flips.

Conclusion

Capricor Therapeutics now sits at a critical crossroads. CAPR is trading like a broken story, not a routine pullback. The FDA advisory committee briefing documents hit deramiocel on its core claims: lack of clear cardiac efficacy, failed pre-specified endpoints, and uncomfortable changes to the statistical analysis plan. A later 9–3 advisory panel vote that deramiocel’s benefits do not outweigh its risks only deepened that damage.

On top of the regulatory blow, the wave of securities-fraud investigations puts a legal cloud over Capricor Therapeutics for months, maybe years. CAPR traders have to factor in the cost of potential settlements, management distraction, and the possibility that future capital raises become more expensive if confidence in the story erodes further.

At the same time, the balance sheet shows Capricor Therapeutics with significant cash and low leverage, which buys time. But that runway is only useful if the pipeline can be rebuilt or deramiocel can be meaningfully repositioned — both open questions after these FDA critiques. CAPR now trades on perception, not traditional valuation metrics.

For active traders studying CAPR, this is where discipline matters most. As Tim Sykes often says, “Volatility is an opportunity, but only for traders who respect risk and cut losses quickly.” That mindset aligns closely with another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” Capricor Therapeutics has become a case study in how fast a biotech narrative can flip when regulatory confidence disappears. Any trading plan around CAPR needs to treat every new FDA or legal headline as a potential catalyst — and size positions accordingly.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!